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Abstract
Background: Many drug users present to primary care requesting detoxification from illicit
opiates. There are a number of detoxification agents but no recommended drug of choice.
The purpose of this study is to compare buprenorphine with dihydrocodeine for
detoxification from illicit opiates in primary care.
Methods: Open label randomised controlled trial in NHS Primary Care (General Practices),
Leeds, UK. Sixty consenting adults using illicit opiates received either daily sublingual
buprenorphine or daily oral dihydrocodeine. Reducing regimens for both interventions were
at the discretion of prescribing doctor within a standard regimen of not more than 15 days.
Primary outcome was abstinence from illicit opiates at final prescription as indicated by a urine
sample. Secondary outcomes during detoxification period and at three and six months post
detoxification were recorded.
Results: Only 23% completed the prescribed course of detoxification medication and gave a
urine sample on collection of their final prescription. Risk of non-completion of detoxification
was reduced if allocated buprenorphine (68% vs 88%, RR 0.58 CI 0.35–0.96, p = 0.065). A
higher proportion of people allocated to buprenorphine provided a clean urine sample
compared with those who received dihydrocodeine (21% vs 3%, RR 2.06 CI 1.33–3.21, p =
0.028). People allocated to buprenorphine had fewer visits to professional carers during
detoxification and more were abstinent at three months (10 vs 4, RR 1.55 CI 0.96–2.52) and
six months post detoxification (7 vs 3, RR 1.45 CI 0.84–2.49).
Conclusion: Informative randomised trials evaluating routine care within the primary care
setting are possible amongst drug using populations. This small study generates unique data
on commonly used treatment regimens.
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Background
In the United Kingdom (UK), policy directives have high-
lighted the importance of offering either maintenance or
detoxification to illicit opiate users within an agreed plan
of care [1]. This is in response to routine practice by some
treatment providers of 'gradual reduction' of opiate main-
tenance treatment – a regimen without a supporting evi-
dence base [2]. Opiate detoxification, using one of various
therapeutic agents, remains an important part of drug
management for some illicit opiate users. However, nei-
ther the evidence base nor UK national guidelines recom-
mend a 'drug of choice' [1]. Understandably, there has
been a call for randomised controlled trials (RCTs) in this
area [3]. In primary care, methadone is commonly used,
with reductions in the dose over 7–21 days [4]. Metha-
done has a long half life [5,6] and patients often report
distressing withdrawal symptoms in the latter stages of
detoxification [6]. This has meant increasing use of alter-
native agents such as clonidine, lofexidine, dihydroco-
deine and, more recently, buprenorphine. The
hypotensive effects of clonidine [4] have make it unac-
ceptable for use in primary care and the reduced ability of
lofexidine to control withdrawal, coupled with its high
cost have resulted in limited clinical uptake [4].
The use of sublingual buprenorphine is relatively new in
the UK for opiate detoxification and there have been only
two randomised controlled trials (RCTs) comparing it
with methadone for this purpose [7,8]. Buprenorphine
has been more commonly used as a drug of comparison
in trials of opiate maintenance [9-16]. A recent Cochrane
review assessing methadone and buprenorphine for the
management of opioid withdrawal found no significant
difference between these two agents [17]. In this context,
buprenorphine has a good safety profile, better retention
in treatment and lower withdrawal severity [18-22]. Sub-
lingual buprenorphine is increasingly being prescribed by
General Practitioners (GPs) for opiate detoxification [23]
despite limited clinical and research evidence.
Dihydrocodeine has a shorter half life than methadone
and has been widely used in both primary care and prison
drug treatment settings for opiate detoxification. Whilst
some commentators have documented success with dihy-
drocodeine [24,25] others have expressed concerns
regarding its effects, particularly the potential diversion
into the street economy [26]. Despite routine use, dihy-
drocodeine has rarely been studied for the purposes of
opiate detoxification [24] but has been compared in a ran-
domised controlled trial with buprenorphine for postop-
erative pain [27].
When comparing methadone, dihydrocodeine and
buprenorphine it is important to note several factors
which may impact upon prescribing and use of these
agents. Dihydrocodeine is cheaper than methadone and
both methadone and dihydrocodeine are substantially
cheaper than buprenorphine. The latter has been subject
to heavy pharmaceutical marketing. Buprenorphine and
dihydrocodeine have a better safety profile than metha-
done, which has a high toxicity which (rarely) can result
in death [28]. All three agents have the potential for street
diversion but dihydrocodeine is the hardest to control,
with consumption usually being unsupervised. Metha-
done is the easiest to manage and buprenorphine seems
to be somewhere in-between.
The care of people using illicit opiates has changed over
recent years. Strang et al (2005) [29] surveyed GPs and
found that half had seen at least one opiate user in a four
week period, compared to only 19% in a 1986 survey
[30]. There has been a significant increase in the number
of GPs becoming involved in the care of drug users [31].
Consequently, many short term opiate detoxifications are
now undertaken in primary care. The absence of robust
evidence underpinning many of the clinical decisions
made within primary care has already been highlighted
[32]. LEEDS (Leeds Evaluation of Efficacy of Detoxifica-
tion Study) is a response to this challenge and compared
dihydrocodeine with buprenorphine for opiate detoxifi-
cation within the UK primary care setting.
Methods
Design and setting
LEEDS was conducted in ten general practices (6 of which
randomised participants) in Leeds, UK (population
~750,000). We used a randomised controlled trial design
to compare open giving of oral dihydrocodeine tartrate
with open giving of sublingual buprenorphine. Randomi-
sation was by random block size, stratified by practice,
using Microsoft Excel RAND function. This was under-
taken by the Department of Psychiatry, University of
Leeds, and was concealed from clinicians prescribing
interventions. The name of the allocated intervention was
obscured within fully opaque sealed envelopes [33]. All
envelopes were opened in strict order, confirmed by an
investigator independent of the clinical interface. The out-
side of the randomisation envelope contained a brief
information form to be completed which requested the
patient's practice number, date of birth, contact telephone
number and date of first prescription. Two questions also
served to rate the severity of addiction of the participant
from the view of the GP. Once the GP/drug worker
opened the LEEDS envelope both practitioner and patient
knew the intervention, standard clinical care resumed and
the patient made subsequent appointments with the GP
and/or drugs worker. To detect with 80% power a differ-
ence in treatment effectiveness of 25% between groups
(50% versus 25%) at 5% level of significance, it was calcu-
lated that 120 participants would be needed in the study.BMC Family Practice 2007, 8:3 http://www.biomedcentral.com/1471-2296/8/3
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However within the time frame for recruitment we were
only able to recruit 60 participants. Randomisation took
place between August 2002 and May 2004. Full methods
are reported elsewhere [33].
The Leeds Teaching Hospitals Local NHS Research Ethics
Committee (LREC) approved the study in April 2002.
Informed written consent was obtained from each patient
following receipt of a participant information leaflet prior
to their involvement in the trial.
Interventions
Buprenorphine was prescribed on an FP10 MDA prescrip-
tion. This allows daily dispensing under supervision of a
pharmacist. Daily supervised administration of dihydroc-
odeine tablets is not possible in the UK as it cannot be pre-
scribed on FP10 MDA prescriptions. As such,
buprenorphine was dispensed either as 8 mg, 2 mg or 0.4
mg sublingual tablet preparation under daily supervision.
Dihydrocodeine was dispensed as 30 mg rapid release tab-
let preparation in take home installments. Each install-
ment was for a minimum of three and a maximum of 4
daily doses. The reducing regimens for both interventions
were at the discretion of the prescribing doctor and within
the standard regimen which was approximately 15 days
(Tables 1 and 2). However, clinicians were free to titrate
doses against withdrawal symptoms. What was being ran-
domised was the open giving of the drugs even if that
meant that participants were not given in the opinion of
the prescribing doctor pharmacologically equivalent dos-
ages.
Inclusion and exclusion criteria
Patients were eligible for the study if they were: aged 18
years or over, using street opiates as confirmed by a urine
sample taken at first assessment, wishing to detoxify
through the standard monitored process, willing to
remain abstinent from opiates and to give informed con-
sent. Patients were excluded if they had contra-indications
to dihydrocodeine or buprenorphine or had been ran-
domised into the trial previously.
Outcomes
The primary outcome was abstinence from illicit heroin at
final prescription, as indicated by urine test. A priori we
classed unsuccessful detoxification as: the final urine
tested positive for metabolic breakdown products of her-
oin (morphine or 6-mono-acetyl morphine); urine tested
positive for opiates commonly found in street heroin
(codeine); the patient did not provide a final urine sam-
ple; did not finish detoxification or reported using street
opiates during the period of detoxification. We recorded
the secondary outcomes of inappropriate use of pre-
scribed medication, overdose and admission to hospital
or Accident and Emergency (A&E) and number of GP/
drug worker visits during the detoxification period. At
three and six month post detoxification, follow up data
were recorded. These outcomes were: whether the person
was still alive, abstinent from opiates, in receipt of sick-
ness certification and their pattern of service use.
Statistical analysis
Outcome data were analysed using Epi Info v 3.3.2 and
SPSS software with relative risk tests for categorical data
and unpaired t-tests for continuous data.
Results
Sixty people using illicit opiates took part in LEEDS (Fig-
ure 1). This comprised of 42 men and 18 women, with an
average age of 28 years. 58% were homeless or unstably
housed. There were no significant differences for those
allocated to one regimen or the other (Table 3).
Overall, only 13 people (23%) completed the prescribed
course of detoxification medication and gave a urine sam-
ple on collection of their final prescription (Table 4).
There was an increased chance of completing the prescrib-
ing regime if allocated buprenorphine though this finding
was of borderline statistical significance (68% vs 88%, RR
0.58 CI 0.35–0.96, p = 0.065). At completion of detoxifi-
cation, by intention to treat analysis we found a higher
proportion of people allocated to buprenorphine pro-
vided a urine sample negative for opiates (abstinent) com-
pared with those who received dihydrocodeine (21% vs
3%, RR 2.06 CI 1.33–3.21, p = 0.028). This suggestion of
an enhanced therapeutic effect with buprenorphine was
negated if we assumed that the proportions of those
returning with clean urine per group were representative
of those who did not return. Had all the medication been
both prescribed and dispensed according to the standard
regimes, an expected mean prescribed dose for each dihy-
Table 1: Standard buprenorphine detoxification
Day Dose (mg)
16
28
38
46
56
64
73 . 6
83 . 2
92 . 8
10 2.4
11 2.0
12 1.6
13 1.2
14 0.8
15 0.4BMC Family Practice 2007, 8:3 http://www.biomedcentral.com/1471-2296/8/3
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drocodeine detoxification would be 4560 mg and 56 mg
for each buprenorphine dose. The actual amount of milli-
grams (mean) and duration of detoxification in days
(mean) prescribed for each dihydrocodeine detoxification
was 4111 mg (90% of expected dose) over 12 days and
32.9 mg (59% of expected dose) of buprenorphine over 9
days (both rounded to nearest day). This would indicate
under-prescribing by doctors for both regimes as 4290 mg
(94% of expected dose) would have expected to be pre-
scribed over 12 days for dihydrocodeine and 47.6 mg
(85% of expected dose) over 9 days for buprenorphine.
There was no statistically significant differences for any
other outcomes although throughout the trial people allo-
cated to buprenorphine did better than those on dihy-
drocodeine. For example people allocated to
buprenorphine had fewer visits to the GP and drugs
worker during detoxification, and more were abstinent at
the three month (10 vs 4, RR 1.55 CI 0.96–2.52) and six
month (7 vs 3, RR 1.45 CI 0.84–2.49) follow up. These
findings were of borderline statistical significance. No
serious adverse events were reported for any participants.
Discussion
Commentators have listed significant barriers to conduct-
ing randomised controlled trials in the primary care set-
ting [34,35]. Barriers certainly may include lack of clinical
equipoise towards interventions and patient preference
for a particular treatment, [36] as well as logistical prob-
lems (principally the busy primary care workplace as not
being conducive to practitioner participation) and over-
optimism regarding recruitment [37]. This study, how-
ever, was at the outset designed collaboratively between
primary care and secondary care researchers to be con-
ducted specifically in the primary care setting. It did not
greatly complicate routine treatment and recorded clear
and concrete outcomes of relevance to the primary care
drug treatment field [33]. The LEEDS project team sought
GPs experience of being involved in the trial through a
cross sectional survey. Details of the practicalities of con-
ducting LEEDS (including recruitment issues and equi-
poise) have been fully described elsewhere [38].
LEEDS is the first randomised controlled trial to compare
buprenorphine and dihydrocodeine for opiate detoxifica-
tion. Sixty people with problems of opiate dependence
agreed to take part in this randomised trial. Thirty five of
these people were recruited from a medical centre for the
homeless. Recruitment of practitioners was problematic
though recruitment of participants was not a substantial
problem for practitioners committed to recruiting into the
trial. This study ran on a very low budget (50% research
assistant time). LEEDS illustrates how such studies, under-
taken in the context of routine care, even with such poten-
tially problematic clientele, are both possible and feasible.
One limitation of LEEDS was that it was underpowered to
detect with confidence clear differences for secondary out-
comes between regimens. Selecting a data collection point
for the primary outcome at completion of detoxification
could be seen as a limitation of the study. However, this
outcome was selected after careful consideration. Ideally
urine collection would be several days post-detoxification
to allow for all prescribed opiates to be clear from the test.
We thought, however, many users would not attend pri-
mary care after completion of detoxification simply to
provide a urine test, particularly as much of the recruit-
ment was from a homeless population who have been tra-
ditionally difficult to engage and retain in treatment
services [39]. Indeed, only 23% of participants provided a
final urine sample. Reasons for this are varied and multi-
ple (Figure 1). Fourteen people did not collect their final
Table 2: Standard dihydrocodeine detoxification
Day Number of 30 mg tablets Morning Midday Evening Night-time
11 8 5 4 4 5
22 0 5 5 5 5
31 8 5 4 4 5
41 6 4 4 4 4
51 4 4 3 3 4
61 2 3 3 3 3
71 0 3 2 2 3
89 2 2 2 3
98 2 2 2 2
10 7 2 1 2 2
11 6 2 1 1 2
12 5 1 1 1 2
13 4 1 1 1 1
14 3 1 1 1
15 2 1 1BMC Family Practice 2007, 8:3 http://www.biomedcentral.com/1471-2296/8/3
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Figure 1
 
 
N.B. Some participants had unsuccessful detoxifications for multiple reasons. 
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prescription and therefore were not available at this time
point to provide a urine sample. Five people never
returned to the GP practice to collect any prescriptions
after their first consultation with the GP or drugs worker.
Additionally, 24 people failed to collect a prescription
somewhere between the second and penultimate. The
high numbers of people who did not provide a urine sam-
ple demonstrates the difficulty in retaining injecting drug
users in treatment services. This pragmatic, low budget
study only sought to record contact with GPs and drugs
workers and did not have sufficient capacity to make per-
sonal contact during the detoxification period to obtain
abstinence status independent of that recorded through
medical contact.
The main objectives of LEEDS were to have some indica-
tion of whether one regimen was associated with better
odds of completing detoxification and to test methods for
larger studies. We recognize that these are limited goals
but found no indication from the literature or even
experts in the field that data was known for these out-
comes. Of course, retention in treatment services post-
detoxification is an important part of the whole treatment
package offered to drug users so we also recorded the fre-
quency of medical service utlisation by participants.
An additional limitation of the study is that we were una-
ble to collect data on the numbers and demographics of
those people who declined to participate. This was due to
the busy nature of the primary care treatment setting.
Currently many drug users arrested for crimes related to
drug misuse are offered a choice of legally mandated treat-
ment (referred to by some as 'coerced' treatment) [40] or
a custodial sentence. No participant in LEEDS had been
legally mandated to enter treatment from the criminal jus-
tice system. Consequently, all participants expressed self
motivation to undergo detoxification. Yet, regardless of
which detoxification drug people were randomised to,
completion rates were poor. This study suggests that even
in this relatively self motivated group of people, comple-
tion rates were between only 13% and 32%. In secondary
care others have reported completion rates in the range of
33% [41]. However comparisons with study retention
rates from trials undertaken in secondary care should be
made with caution as it is possible that participants were
not equivalent in terms of motivation and self-efficacy.
More evaluation of treatment effects in different health
settings would therefore seem prudent and we have nearly
completed a larger study in the prison setting. The results
of this current study, however, are generalisable to those
patients presenting for detoxification from illicit opiates
in primary care. We would be less confident of generalis-
ing our findings to the residential or inpatient setting.
This trial suggests that buprenorphine may be able to
deliver 20% more completion than dihydrocodeine. If
Table 3: Demographic characteristics and prognostic factors
Buprenorphine (total 28) Dihydrocodeine (total 32)
Age mean (SD) 29.9 (5.1) 29.0 (7.3)
Sex 19 M 9 F 23 M 9 F
Pattern of use
How are opiates taken?
IV 14 (50%) 24 (75%)
Smoking 13 (46%) 8 (25%)
Both 1 (4%) 0
Current daily use (minimum) (£) mean 17.1 (8.1) 15.6 (7.2)
Current daily use maximum (£) mean 23.2 (12.1) 18.1 (9.0)
Duration taking opiates (years) mean 8.8 (4.9) 7.0 (3.7)
Illicit opiates in initial urine 23 (82%) 27 (84%)
Other drugs in initial urine 18 (64%) 12 (37%)
Prognostic factors
'Severely dependent' 8 (28%) 10 (31%)
GP's prediction of whether would be off 
opiates by end of detox
Definitely not Not sure Very sure Definitely not Not sure Very sure
0 22 (78%) 6 (21%) 2 (6%) 22 (69%) 8 (25%)
Y e sN o D / KY e sN o D / K
Previous detoxes? 24 (87%) 3 (11%) 1 (4%) 25 (78%) 6 (19%) 1 (3%)
Successful detoxes? 15 (63%) 9 (38%) 0 15 (60%) 9 (36%) 1 (4%)
Employed? 4 (14%) 19 (68%) 5 (18%) 4 (13%) 19 (59%) 9 (28%)
MED-3? 6 (21%) 8 (29%) 14 (50%) 5 (16%) 13 (41%) 14 (44%)
Non using friends? 12 (43%) 5 (18%) 11 (39%) 13 (41%) 3 (9%) 16 (50%)
Anyone supportive of detox? 22 (79%) 4 (14%) 2 (7%) 24 (75%) 1 (3%) 7 (22%)BMC Family Practice 2007, 8:3 http://www.biomedcentral.com/1471-2296/8/3
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completion of detoxification is associated with remaining
abstinent, use of buprenorphine as an agent of opiate
detoxification could be a very important step forward.
Whilst clinicians prescribing the interventions were not
blinded beyond the point of randomisation, the differ-
ence favouring buprenorphine could be due to increased
professional input for that intervention. However there
was no evidence to suggest that this was the case. Rather,
there was no suggestion of a difference in GP/drug worker
visits between the two groups. LEEDS was a "real-world"
trial with a pragmatic rather than explanatory design. As
such it randomised interventions which are used in every-
day clinical practice. Previous commentators have spoken
about the need to balance issues of methodological rigour
(commonly referred to as internal validity) versus the fea-
sibility of conducting trials in the real world clinical envi-
ronment (commonly referred to as external validity) [42].
Inevitably there is a trade off between rigour and feasibil-
ity. For example in this case whilst the use of dummy pills
was considered at the design stage, it was deemed unfeasi-
ble as it would both add to the cost of the research and
also limit the independence of the trial from pharmaceu-
tical company funding.
It could also be argued that the superior percentage of
those achieving abstinence as a result of the buprenor-
phine intervention was because mean buprenorphine and
dihydrocodeine doses were not equivalent in terms of the
pharmacological opiate effect. However this is not possi-
ble to verify as the two interventions are not identical in
terms of action on opiate receptors. Buprenorphine has
the unusual property of being both a partial MU receptor
(one of a number of opiate receptors) agonist and partial
opiate antagonist whereas dihydrocodeine is a full opiate
receptor agonist.
Conclusion
Only 23% of participants completed their detoxification
and gave a final urine sample. This finding suggests a high
non-completion rate of primary care opiate detoxifica-
tions. A higher proportion of people randomised to
buprenorphine provided a final urine sample negative for
Table 4: Results
Buprenorphine 
(total 28)
Dihydrocodeine 
(total 32)
Odds Ratio (95% CI) Relative Risk (95% CI) P value
By end of detox
Final urine sample 9 (32%) 4 (13%) 3.32 (0.77–15.22) 1.71 (1.04–2.83) 0.065
Non-ITT Clean urine 6/9 (67%) 1/4 (25%) 6.00 (0.28–246) 1.71 (0.73–4.03) 0.164
ITT-1* clean urine 6/28 (21%) 1/32 (3%) 8.45 (0.89–200) 2.06 (1.33–3.21) 0.028
ITT-2* clean urine 6+3/28 1+8/32 1.21 (0.35–4.21) 1.11 (0.63–1.95) 0.735
Leaving early 19 (68%) 28 (88%) 0.30 (0.07–1.30) 0.58 (0.35–0.96) 0.065
Overdose 0 0 Not applicable
Inappropriate use of 
allocated drug
0 0 Not applicable
A&E attendance 0 0 Not applicable
Admitted 0 0 Not applicable
Overdose 0 0 Not applicable
GP visits – mean 2.2 (1.05) 2.8 (1.33) 0.06
Drug worker visits – mean 0.17 (0.47) 1.31 (0.59) 0.343
At 3 months post detoxification
Abstinent 10/27 (37%) 4/24 (17%) 2.94 (0.67–13.78) 1.55 (0.96–2.52) 0.104
Dead 0/27 0/28 Not applicable
On Med 3 sick note 10/16 (63%) 6/14 (43%) 2.22 (0.41–12.65) 1.46 (0.71–2.98) 0.282
A&E attendance 2/27 (7%) 2/28 (7%) 1.04 (0.09–11.46) 1.06 (0.38–2.94) 0.970
Hospital attendance 1/27 (4%) 2/28 (7%) 0.5 (0.02–7.75) 0.67 (0.13–3.38) 0.574
GP visits – mean 5.04 (4.85) 4.61 (4.10) 0.724
Drug worker visits – mean 1.22 (1.67) 1.14 (1.53) 0.855
At 6 months post detoxification
Abstinent 7/22 (32%) 3/19 (16%) 2.49 (0.45–15.15) 1.45 (0.84–2.49) 0.233
Dead 0/23 0/20 Not applicable
On Med 3 sick note 3/11 (27%) 2/11 (18%) 1.69 (0.16–20.05) 1.27 (0.53–3.06) 0.611
A&E attendance 0/22 0/20 Not applicable
Hospital attendance 0/22 2/20 (10%) 0.16 (0.01–3.64) 0.129
GP visits – mean 7.54 (6.71) 6.48 (6.07) 0.582
Drug worker visits – mean 1.74 (2.40) 2.65 (2.89) 0.265
• Assumption 1 = everybody not returning for final urine test had not clean urine
• Assumption 2 = everybody not returning for final urine test had same proportion of not clean urine as those who didBMC Family Practice 2007, 8:3 http://www.biomedcentral.com/1471-2296/8/3
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illicit opiates compared with those who received dihy-
drocodeine. Those allocated buprenorphine made fewer
visits to the GP and drugs worker during detoxification.
Additionally, more of those allocated buprenorphine
were abstinent at three and six months post detoxification
when compared to the dihydrocodeine group.
Currently in some treatment services in the UK the open
giving of dihydrocodeine has continued despite an
absence of evidence to support its clinical effectiveness.
More recently, there has been a marked increase in the
prescribing of buprenorphine in the UK [23]. Such an
increase is in line with emerging best practice primary care
guidance based primarily upon face validity for opiate
detoxification. This guidance supports the use of
buprenorphine but not dihydrocodeine for opiate detoxi-
fication in the primary care setting [43]. The LEEDS find-
ings begin to support this guidance with good evidence
but there is some way to go before fully confident recom-
mendations can be made.
The findings will also have relevance to any review of cur-
rent Department of Health best practice guidelines for the
treatment of substance misuse [4]. Launched in 1999,
they argued that GP prescribing of buprenorphine
requires a greater level of clinical experience than the pre-
scribing of dihydrocodeine. The guidelines recommend
buprenorphine should only be given by a "specialist gen-
eral practitioner" and dihydrocodeine by an "experi-
enced" GP [4]. LEEDS provides little evidence to support
the continued prescribing of dihydrocodeine as a first line
agent for opiate detoxification by less experienced GPs in
primary care, but larger, well designed, conducted and
reported trials are necessary.
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